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Objective. To investigate an effect of smoking cessation on chronic obstructive pulmonary 1 
disease (COPD) mortality in Asians. 2 
Method. The data was obtained from the Japan Collaborative Cohort Study for Evaluation 3 
of Cancer Risk (JACC Study). A total of 41,465 Japanese men and 52,662 Japanese women 4 
aged 40-79 years who had no history of COPD, asthma, other chronic lung diseases, 5 
cardiovascular disease or cancer were followed between 1988 and 2008. 6 
Results. During median 18-year of follow-up, there were 285 (251 men and 34 women) 7 
documented deaths from COPD. Multivariable-adjusted hazard ratios with 95% confidence 8 
intervals of COPD death were 4.46 (2.72-7.29) and 9.26 (4.19-20.5), respectively for 9 
current male and female smokers when compared to never smokers. Compared with current 10 
smokers, the multivariable HRs for 5-9 years and 10 years or more smoking cessation prior 11 
to baseline were 0.44 (0.22-0.87) and 0.36 (0.22-0.58) in men, respectively while the HR 12 
for never smokers was 0.30 (0.16-0.57). There were an insufficient number of COPD 13 
deaths in women to clarify this association.  14 
Conclusion. Smoking cessation for ten years or more prior to enrollment reverses the 15 
excess risk of COPD mortality to a level similar to that observed among never smokers in 16 
men. 17 
Keywords: Smoking Cessation; COPD; Mortality; Prospective Study; Epidemiology 18 
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Introduction 19 
Chronic obstructive pulmonary disease (COPD) is a long-standing, crippling disease 20 
characterized by accelerated decline of lung function. The disease is commonly brought by 21 
aging and long-term tobacco smoking(Burrows et al., 1977; Fletcher and Peto, 1977). The 22 
latest report from World Health Organization described that COPD is the only major cause 23 
of deaths that has increased in recent years and that it is predicted to become the third 24 
leading cause of death worldwide by 2030, both are due to the expansion of smoking habit 25 
in developing world and increasing life expectancy(WHO report, 2008). Recent updated 26 
international guidelines define COPD as a preventable and treatable disease by smoking 27 
cessation that convincingly palliates the accelerated lung function decline(Rabe et al., 28 
2007).  29 
Several prospective studies have described lower COPD mortality risks in former 30 
smokers compared to continuous smokers(Carstensen et al., 1987; Doll et al., 1980; Doll et 31 
al., 2004; Rogot and Murray, 1980). However, they were worksite-based studies in male 32 
Caucasians(Carstensen et al., 1987; Doll et al., 2004; Rogot and Murray, 1980), except for 33 
one study conducted in women(Doll et al., 1980). Moreover, no studies have addressed 34 
whether there may be certain duration of smoking cessation that would significantly reduce 35 
risk of COPD mortality to the level similar to never smokers.  36 
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The detailed examination of this issue would enable us to formulate more an explicit 37 
public health recommendation. Therefore, in this 18-year follow-up cohort study of 38 
approximately 95,000 Japanese men and women, we examined risk of COPD mortality 39 
associated not only with smoking status but time since quitting smoking.  40 
 41 
Methods 42 
The Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC study) was 43 
initiated 1988-1990(Kawado et al., 2005; Ohno and Tamakoshi, 2001). Self-administered 44 
questionnaires that included items on lifestyles and medical histories of COPD, cancer, 45 
cardiovascular disease and other diseases were completed by 110,792 persons(46,465 men 46 
and 64,327 women) aged 40-79 years from 45 communities across Japan. Among them, 47 
44,201 men and 55,592 women provided valid responses about smoking status. Those who 48 
had quit smoking were asked at what age or what year they stopped in order to calculate the 49 
years of smoking cessation. We also excluded 2,736 men and 2,930 women with a reported 50 
history of COPD, asthma, other chronic lung diseases, cardiovascular disease or cancer at 51 
baseline, leaving 41,465 men and 52,662 women for the present analysis.  52 
Mortality surveillance was conducted systematically by reviewing death certificates. 53 
The underlying causes of death according to the International Classification of Diseases 54 
(ICD-10) were obtained centrally from the Ministry of Health and Welfare. COPD was 55 
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defined as ICD-10 codes of J41 to J44 and J47. The present study was approved by the 56 
Ethical Committee, Nagoya University and Osaka University. 57 
Statistical Analysis 58 
Participants were followed-up until death or they moved away from the original 59 
community to the end of 2008. The follow-up of six and five communities ended at the end 60 
of 1999 and 2003, respectively. Median follow-up period was 18 years. Sex-specific, 61 
age-adjusted means and proportions of selected COPD risk factors were calculated by general 62 
linear model.  63 
Sex-specific, age-adjusted and multivariable-adjusted hazard ratios(HRs) and their 95% 64 
confidence intervals(95% CIs) were calculated by Cox proportional hazards models. Duration 65 
of smoking cessation was divided to three groups (0-4, 5-9 and ≥10 years before the baseline). 66 
Variables included in the multivariable-adjusted model were age at baseline, body mass index, 67 
ethanol intake, hours of walking, hours of exercise, education, perceived mental stress, and 68 
histories of hypertension and diabetes. Number of cigarettes smoked per day and age of 69 
smoking initiation were also included in the smoking cessation analysis. 70 
Sensitivity analyses were conducted separately by excluding early deaths from COPD 71 
mortality within the first 5-year of follow-up and by excluding those with self-reported 72 
persistent phlegm symptom in an attempt to reduce a reverse causal relationship. Interaction 73 
for sex-by-smoking status was tested by using cross-product terms of sex with smoking status. 74 
In order to evaluate the specificity of association of smoking status or smoking cessation 75 
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duration with COPD mortality, all-cause mortality was also modeled, and the result was 76 
compared with that of COPD. This was done by computing a test statistic: 77 
(bl-b2)2/{[SE(b1)]2+[SE(b2)]2}, where b1 is the coefficient for the association with COPD, b2 78 
is the coefficient for all-cause mortality, SE(b1) and SE(b2) are the corresponding standard 79 
errors for the association with COPD and all-cause mortality, respectively(Allison, 1995).  80 
The proportional hazards assumption was confirmed graphically by examining the 81 
parallelness of the ln (-ln) survival curves for smoking status as well as by a model including 82 
the interaction term between follow-up time and smoking status. The follow-up time was first 83 
treated as a continuous scale and then dichotomized at year 11 (middle value of follow-up) in 84 
the model. We found no violation for the proportional hazard assumption. 85 
All analyses were performed by using SAS version 9.1.3 Service Pack 4 (SAS Institute, 86 
Cary, North Carolina). Two-tailed probability values of <0.05 were considered statistically 87 
significant. 88 
 89 
Results 90 
The proportions of current and former smokers were 54% and 25% in men, and 6% and 91 
2% in women, respectively. Majority of male smokers (68%) smoked 20 or more cigarettes 92 
per day, but the corresponding proportion in female current smokers were 31%. Compared 93 
with never or current smokers, former smokers were older, more educated, and more likely to 94 
have hypertension and diabetes mellitus in both men and women (Table 1).  95 
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A total of 251 deaths from COPD among 41,465 men and 34 deaths among 52,662 96 
women were documented during the 18-year follow-up. Both former and current smoking 97 
were significantly associated with increased COPD mortality for both men and women in 98 
models adjusted for age and potential confounding variables (Table 2). The 99 
multivariable-adjusted HRs (95% CIs) for former and current smokers compared with never 100 
smokers were 2.97 (1.76-5.02) and 4.46 (2.72-7.29) in men and 8.57 (2.75-26.7) and 9.26 101 
(4.19-20.5) in women, respectively (Table 2). There appeared dose-response associations 102 
between the number of cigarettes smoked daily and age- and multivariable-adjusted risk of 103 
COPD mortality among current smokers in both sexes. Although crude COPD mortality rates 104 
were higher in men than in women in any smoking status categories at baseline, associations 105 
of both former and current smoking with COPD mortality tended to be stronger in women 106 
than in men (P for sex-by-smoking status interaction =0.08). 107 
Compared with current smokers, former smokers at baseline were associated with lower 108 
COPD mortality in men but only when cessation duration was five years or more before the 109 
baseline (Table 3). Men who had quit smoking more than 10 years before baseline had COPD 110 
mortality risk close to never smokers. Quitters for less than five years did not experience the 111 
lowering of mortality risk compared to current continuous smokers. The finding did not 112 
change materially even after excluding COPD deaths that occurred within five years from the 113 
baseline or individuals who reported persistent phlegm symptom at baseline (HRs: 95% CIs 114 
were 1.19 0.80-1.79 and 1.11: 0.71-1.72, respectively). There were too few death cases in 115 
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female former smokers (n=4) at each smoking cessation group to yield meaningful results. 116 
The associations of smoking status (P=0.005 in men, P<0.001 in women) and 117 
smoking cessation duration (P<0.001 in men) with COPD mortality were stronger than 118 
those with all-cause mortality (Supplemental tables 1 and 2). 119 
 120 
Discussion 121 
We observed the excess risk of COPD mortality among current and former smokers of 122 
both sexes in this large prospective cohort study of Japanese. Our finding is consistent with 123 
the results from previous prospective studies, including US veterans cohort(Rogot and 124 
Murray, 1980), British doctors’ cohort(Doll et al., 1980; Doll et al., 2004), Swedish registers’ 125 
cohort(Carstensen et al., 1987), Copenhagen registers’ cohort(Lange et al., 1992), and 126 
Washington white registers’ cohort(Tockman and Comstock, 1989). 127 
Our study also revealed that the duration of smoking cessation was inversely associated 128 
with COPD mortality in men, and the excess risk that would have been observed if they had 129 
continuous smoking could be reduced after long-term (≥10 years) cessation before the 130 
baseline similar to the level observed in never smokers. 131 
A few studies have evaluated the duration of quitting smoking associated with COPD 132 
mortality and morbidity(Lokke et al., 2006; Rogot and Murray, 1980). Our finding that 133 
accounted for other smoking-related variables, which previous studies did not address, was 134 
similar to that of a 25-year follow-up study in a general population of both sexes(Lokke et al., 135 
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2006). That study showed a dose-response relationship between the duration of smoking 136 
cessation and cumulative incidence of COPD, and the odds ratio for stage 2 or more COPD in 137 
ex-smokers who had quit 25 years or more at the end of follow-up compared to continuous 138 
smokers was similar to that in never smokers(Lokke et al., 2006). Another 16-year 139 
observation in the US veterans described that crude COPD mortality rate fell to 140 
approximately one fifth of continuous smokers if subjects had quit smoking 20 years or more 141 
at the end of follow-up(Rogot and Murray, 1980). 142 
It is noteworthy that both former and current smokers were more strongly associated with 143 
COPD mortality in women than in men, especially in female heavy smokers who currently 144 
smoked 20 or more cigarettes per day. The interaction for sex-by-smoking status was found to 145 
be of borderline significance (P=0.08) in the multivariable model. Similarly, Copenhagen 146 
City Heart Study(Lange et al., 1992) and British doctors’ cohort study(Doll et al., 1980; Doll 147 
et al., 2004) also presented that the COPD mortality ratio associated with smoking in female 148 
was higher than that in male, however the number of female deaths from COPD was too 149 
small in both studies to confirm the gender difference. The higher age-adjusted relative risks 150 
for COPD hospitalization in female smokers compared the risk in male smokers was also 151 
observed in Danish longitudinal population study (P=0.08 for the interaction for sex by 152 
pack-years categories). Previous prospective studies demonstrated that at comparable levels 153 
of smoking exposure, women expressed a faster decline in lung function (FEV1)(Prescott et 154 
al., 1997; Xu et al., 1994). A possible explanation for the faster deterioration is that women 155 
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have smaller airways and lung volume than dose men, which results in higher exposure in per 156 
volume of lung tissues with each cigarette. In addition, estrogen and related compounds have 157 
been reported to increase smoking-induced lung damage possibly through up-regulating the 158 
expression of cytochrome P450 enzymes in lungs(Benowitz et al., 2006). Cytochrome P450 159 
enzymes facilitate to transform some harmless substances in cigarette smoke into toxic 160 
chemicals, for example benzo[a]pyrene into benzo[a]pyrene-7,8-diol (Ben-Zaken Cohen et 161 
al., 2007). A family study of early-onset COPD probands found no differences in lung 162 
function between their female and male first-degree relatives. However, smoking female 163 
first-degree relatives, women showed significantly lower lung function than smoking male 164 
first-degree relatives ,which implied a genetic predisposition for smoking-induced lung 165 
damage in women(Silverman et al., 2000). In the current study, the misclassification of 166 
smoking status as never smoking in women was smaller than that in men, which may 167 
contribute to the stronger association between smoking and mortality in women. In addition, 168 
the finding might have been observed by chance due to small number of women who died 169 
from COPD. 170 
Potential effects of smoking cessation on pulmonary pathology have been reported. 171 
Macroscopic signs of chronic bronchitis (edema, erythema and mucus) disappeared totally 172 
after 6 months’ smoking cessation(Skold et al., 1992). In addition, after smoking cessation, 173 
the number of macrophages in bronchoalveolar lavage fluid(Skold et al., 1992), blood 174 
neutrophils and lymphocytes(Jensen et al., 1998) was largely reversed, and those in 175 
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bronchoalveolar lavage fluid normalized at 6, 9, 15 months, respectively(Skold et al., 1996). 176 
These data indicated that the inflammatory changes are reversible rapidly after smoking 177 
cessation. However, in the present study, quitters for less than five years did not experience 178 
the lowering of COPD mortality risk compared to current continuous smokers. One possible 179 
explanation is that the sample in the present study included people who already had 180 
preclinical but irreversible emphysema. Indeed, a recent study in Japan showed that only 181 
9.4% of cases with airflow limitation reported a previous diagnosis of COPD(Fukuchi et al., 182 
2004). Even among early stage COPD patient, it takes 11-years or more for sustained quitters 183 
to experience the same rate of FEV1 decline as never smokers(Anthonisen et al., 2002). 184 
We could not clarify the association between the duration of smoking cessation and 185 
COPD mortality in women due to the small number of deaths in former smokers. However, 186 
one previous intervention study demonstrated that women experienced larger improvements 187 
in lung function with smoking cessation than men (▵FEV1 change: 3.7% vs. 1.6%)(Connett et 188 
al., 2003). The effect of smoking cessation on COPD incidence and mortality in women 189 
warrants further investigation.  190 
Since persons who quit smoking years prior to the enrollment were more likely to be 191 
unhealthy or had some respiratory symptoms, we conducted analyses by excluding the early 192 
deaths of COPD within 5-year of follow-up or those who had persistent phlegm at baseline. 193 
This exclusion, however, did not alter our results essentially.  194 
Some limitations in the present study merit discussion. COPD develops in a long-term 195 
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process and is often undiagnosed(Fukuchi et al., 2004; Mannino et al., 2000). Therefore, the 196 
duration of smoking cessation to reduce mortality from COPD (≥10 year before baseline) 197 
might be longer than that to reduce the incidence of COPD. Smoking information was 198 
assessed only at baseline and was not updated throughout the entire study period in the 199 
present study. However, the examination of about one-third of the present sample with 5-year 200 
follow-up data indeed showed that the percentage of current smokers had decreased(Kawado 201 
et al., 2005) by 5.6 point for men, 0.4 point for women in the present study sample. This 202 
suggests that the beneficial effect for smoking cessation may be underestimated, especially 203 
for men. 204 
Our study takes advantages of a long observation period, a large population-based 205 
samples and the availability of information about potential confounding factors for COPD. 206 
We have found that smoking status and smoking cessation duration were more strongly 207 
associated with COPD than with all-cause mortality. 208 
Overall, the present study suggests that women may be more susceptible to smoking 209 
cigarettes for COPD mortality, and that longer time of smoking cessation was associated with 210 
progressively decreased COPD mortality in men. We conclude that smokers should be 211 
encouraged to stop smoking as early as possible for the prevention of COPD. 212 
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Table 1. Sex-specific, age-adjusted means and proportions according to smoking status at baseline, Japan Collaborative Cohort Study for Evaluation of Cancer Risk (JACC Study), 
1988-2008. 
  
Men 
  
Women 
Never 
smokers 
Former 
smokers 
Current 
smokers 
Cigarettes smoked* 
(no./day) Never 
smokers 
Former 
smokers 
Current 
smokers 
Cigarettes smoked* 
(no./day) 
1–19 ≥20 1–19 ≥20 
No. at risk 8,613 10,394 22,458 7,174 14,973 48,914 853 2,895 1,932 848 
Age (years) 56.6  60.0  55.9  59.0  54.4  57.1  60.0  56.0  56.7  54.2  
Body mass index (kg/m2) 23.0  22.9  22.4  22.0  22.6  22.9  23.3  22.8  22.7  23.2  
History of hypertension (%) 19.1  26.0  17.8  21.4  16.0  21.6  27.4  22.2  23.2  20.2  
History of diabetes (%) 5.7  8.4  6.2  6.7  6.1  3.5  6.8  5.0  4.8  4.5  
Ethanol intake (g/day) 18.2  22.5  27.4  24.4  28.9  1.2  4.7  6.9  5.5  10.5  
Walk half an hour or more/day (%) 69.3  68.2  69.8  71.1  69.3  71.9  64.5  69.3  70.8  66.2  
Exercise 5 hours or more/week (%) 7.2  8.3  6.6  8.0  5.9  4.5  4.3  4.0  4.3  3.2  
High perceived mental stress (%) 22.4  21.8  23.9  19.7  25.9  20.0  24.1  26.2  24.1  30.7  
College or higher education (%) 18.3  20.2  15.9  15.2  16.3  10.1  12.5  8.5  9.1  7.5  
* Information on number of cigarettes smoked per day among current smokers was missing for 311 men and for 115 women.       
  300 
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Table 2. Sex-specific, age- and multivariable-adjusted hazard ratios and 95% confidence intervals of mortality from COPD according to smoking status, Japan Collaborative Cohort 
Study for Evaluation of Cancer Risk (JACC Study), 1988-2008. 
  
Never                     
smokers 
Former        
smokers 
Current                
smokers 
Cigarettes smoked 
(no./day) 
1–19 ≥20 
Men 
No. at risk 8,613 10,394 22,458 7,174 14,973 
No. of person-years 138,752  157,215  346,870  106,398  235,693  
No. of death 18  68  165  53  111  
Crude death rate* 13 43 48 50 47 
Age-adjusted HR 1.0  2.76 (1.64-4.64) 4.84 (2.97-7.88) 3.57 (2.09-6.09) 6.06 (3.67-10.0) 
Multivariable HR† 1.0  2.97 (1.76-5.02) 4.46 (2.72-7.29) 3.27 (1.91-5.60) 5.60 (3.38-9.29) 
            
Women 
No. at risk 48,914 853 2,895 1,932 848 
No. of person-years 796,017  12,463  44,454  29,454  13,099  
No. of death 20  4  10  6  4  
Crude death rate* 3 32 22 20 31 
Age-adjusted HR 1.0  8.82 (3.01-25.9) 10.1 (4.71-21.6) 8.35 (3.35-20.8) 19.3 (6.58-56.4) 
Multivariable HR† 1.0  8.57 (2.75-26.7) 9.26 (4.19-20.5) 7.54 (2.95-19.3) 18.3 (5.96-56.3) 
*: Mortality rate was expressed as rate per 100,000 person-years.         
†: Multivariable adjustment: age (continuouse), body mass index (sex-specific quintiles), ethanol intake (never, former, current intake of 1–22, 23–45, 46–68, and ≥69 g per day), 
hours of walking (<0.5, 0.5, 0.6–0.9, and ≥1.0 hour per day), hours of exercise (<1, 1–2, 3–4, and ≥5 hours per week), education (<10, 10–12, 13–15, and ≥16 years), perceived mental 
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stress (low, medium, and high), and histories of hypertension and diabetes. 
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Table 3. Sex-specific, age- and multivariable-adjusted hazard ratios and 95% confidence intervals of mortality from COPD according to years since quitting, Japan Collaborative 
Cohort Study for Evaluation of Cancer Risk (JACC Study), 1988-2008. 
  
Current           
smokers 
  
No. of years since quitting smoking before the baseline*  
  
Never             
smokers 
0-4 5-9 ≥10 
Men           
No. at risk 22,458 2,599 2,360 4,964 8,613 
No. of person-years 346,870 39,582 35,889 74,612 138,752 
No. of death 165 32 9 20 18 
Crude death rate** 48 81 25 27 13 
Age-adjusted HR 1.0  1.24 (0.85-1.82) 0.41 (0.21-0.80) 0.30 (0.19-0.48) 0.21 (0.13-0.34) 
Multivariable HR† 1.0  1.23 (0.83-1.81) 0.44 (0.22-0.87) 0.36 (0.22-0.58) 0.30 (0.16-0.57) 
            
Women           
No. at risk 2,895 251 184 315 48,914 
No. of person-years 44,454 3,758 2,657 4,510 796,017 
No. of death 10  0  2  2  20  
Crude death rate** 22 0 75 44 3 
Age-adjusted  HR 1.0  -----------------------1.00 (0.31-3.18)----------------------- 0.10 (0.05-0.21) 
*: Information on number of years since quitting smoking was missing for 471 men and for 103 women. 
**: Mortality rate was expressed as rate per 100,000 person-years. 
†: Multivariable adjustment: variables included in multivariable model  in table 2 plus number of cigarettes smoked per day (<20, 20–29, and ≥30) and age of smoking initiation 
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(<20, 20–24, 25–29, and ≥30 years).  
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